logo
Twitter
Discord
Email
logo
BioLineRx Ltd.

BioLineRx Ltd.

NASDAQ•BLRX
CEO: Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2011-07-27
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Contact Information
Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, 7177871, Israel
972-8-642-9100
www.biolinerx.com
Market Cap
$12.53M
P/E (TTM)
-1.4
38.2
Dividend Yield
--
52W High
$7.77
52W Low
$2.30
52W Range
11%
Rank65Top 96.0%
1.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$4.94M+0.00%
4-Quarter Trend

EPS

-$1.47+1900.00%
4-Quarter Trend

FCF

$0.00+0.00%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Massive Revenue Jump Total revenues reached $28.9M in 2024, a 502.1% increase, driven by upfront and milestone payments from licensing deals.
Net Loss Significantly Narrows Net loss improved substantially to ($9.2M) in 2024 from ($60.6M) in 2023, reflecting reduced operating expenses post-restructuring.
Successful Capital Raising Net cash provided by financing activities was $20.7M in 2024, supported by registered direct offerings completed in late 2024 and early 2025.
R&D Costs Decreased Research and development expenses fell 26.4% to $9.2M in 2024, following termination of AGI-134 development and US commercial shutdown.

Risk Factors

Going Concern Material Uncertainty Management concluded substantial doubt about ability to continue as going concern, despite recent financing efforts providing runway through H2 2026.
Partner Commercialization Dependency Future revenue hinges on licensees (Ayrmid, Gloria) successfully commercializing APHEXDA across licensed territories and indications.
Israeli Geopolitical Instability Operations based in Israel face adverse effects from ongoing political, economic, and military instability in the region, impacting business continuity.
Biokine Arbitration Claim Biokine filed complaint seeking $6.5M damages for alleged breach; dispute referred to arbitration, outcome remains uncertain for proprietary technology rights.

Outlook

Cash Runway Secured Existing cash and expected partnership inflows provide sufficient capital requirements through the second half of 2026.
Refocused Israeli Development Operations refocused on development activities in Israel for oncology and rare diseases, achieving a significantly reduced annual cash burn rate.
Pipeline Expansion Strategy Actively pursuing in-licensing opportunities to expand and diversify product pipeline, focusing on assets complementing core expertise in oncology/rare disease.
Future Financing Exploration Expect to continue exploring alternative financing sources, including future securities offerings and government grants, to support ongoing development objectives.

Peer Comparison

Revenue (TTM)

Editas Medicine, Inc.EDIT
$46.38M
-24.9%
BioLineRx Ltd.BLRX
$17.25M
-21.6%
Annexon, Inc.ANNX
$3.40M
-30.0%

Gross Margin (Latest Quarter)

Lyell Immunopharma, Inc.LYEL
100.0%
+0.0pp
Editas Medicine, Inc.EDIT
100.0%
+2621.3pp
BioLineRx Ltd.BLRX
83.4%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ANNX$725.94M-4.4-92.3%11.8%
REPL$552.22M-2.1-82.8%19.6%
LYEL$504.76M-1.3-96.7%10.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-25.1%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 30, 2026
|
EPS:-$0.50
|
Revenue:-
Reports
All Years

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 31, 2025|
    Revenue: $28.94M+502.9%
    |
    EPS: $-0.12+87.8%
    Beat

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 26, 2024|
    Revenue: $4.80M+0.0%
    |
    EPS: $-0.94-95.3%
    Beat

  • Form 20-F/A - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 26, 2024|
    Revenue: $4.80M+0.0%
    |
    EPS: $-0.94-95.3%
    Beat

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Mar 22, 2023|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.48+21.1%
    N/A

  • Form 20-F/A - FY 2021

    Period End: Dec 31, 2021|Filed: Sep 9, 2022|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.61+66.0%
    N/A

  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Mar 16, 2022|Refer to amended data

  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: Feb 23, 2021|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.80+33.3%
    N/A